|
|
Volumn 1, Issue 3, 1990, Pages 331-362
|
|
The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
RECOMBINANT DNA;
ARTICLE;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
CHILD;
ETHICS;
GENE THERAPY;
GENETICS AND REPRODUCTION;
GOVERNMENT;
GOVERNMENT REGULATION;
HEALTH CARE ORGANIZATION;
HUMAN;
HUMAN EXPERIMENT;
HUMAN GENE THERAPY SUBCOMMITTEE;
IMMUNE DEFICIENCY;
METHODOLOGY;
NATIONAL INSTITUTES OF HEALTH;
PATIENT SELECTION;
POINTS TO CONSIDER: TRANSFER OF RECOMBINANT DNA INTO HUMAN SUBJECTS;
RESEARCH SUBJECT;
SOCIAL CONTROL;
STANDARD;
TECHNIQUE;
UNITED STATES;
BIOMEDICAL AND BEHAVIORAL RESEARCH;
GENETICS AND REPRODUCTION;
HUMAN GENE THERAPY SUBCOMMITTEE;
NATIONAL INSTITUTES OF HEALTH;
POINTS TO CONSIDER: TRANSFER OF RECOMBINANT DNA INTO HUMAN SUBJECTS;
CHILD;
DNA, RECOMBINANT;
ETHICAL REVIEW;
ETHICS;
FEDERAL GOVERNMENT;
GENE THERAPY;
GOVERNMENT;
GOVERNMENT REGULATION;
HUMAN EXPERIMENTATION;
HUMANS;
IMMUNOLOGIC DEFICIENCY SYNDROMES;
METHODS;
NATIONAL INSTITUTES OF HEALTH (U.S.);
PATIENT SELECTION;
REFERENCE STANDARDS;
RESEARCH DESIGN;
RESEARCH SUBJECTS;
SOCIAL CONTROL, FORMAL;
UNITED STATES;
|
|
EID: 0025486836
PISSN: 10430342
EISSN: None
Source Type: Journal
DOI: 10.1089/hum.1990.1.3-331 Document Type: Article |
|
Times cited : (111)
|
|
References (0)
|
